MRK

Health Technology
$113.41 -0.04%
Back to Screener
Live Volume
5,208,051
Market Cap
280.1 B
P/E Ratio
31.92
52W Peak Proximity
%91

ANALYSIS CENTER

AI Rating & Analysis: MRK stock analysis with hallucination-free AI screener tools — real-time price, volume, P/E ratio, 52-week proximity and sector performance data for Health Technology. AI-powered stock analysis and research platform.
GOD-TIER PROMPT ACTIVE
Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level
10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.
1Executive Summary
2Fair Value
3Fundamental Analysis
4Technical Analysis
5Scenario Analysis
6Competitor Comparison
7Dividend Return
8Risk Analysis
9Catalyst Calendar
10Action Plan
HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.
İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.
Open Advanced Chart
TradingView Charts
• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — MRK

Merck & Co., Inc. — Company Profile & Analysis

Merck & Co., Inc. operates as a global healthcare company dedicated to improving human health through innovative medicines and vaccines. Founded in 1891, the company has a long-standing history of scientific discovery and a steadfast commitment to patient care. Merck's core mission is to tackle the world's most challenging diseases and enhance the quality of life for people everywhere. In pursuit of this vision, the company provides solutions for a wide spectrum of medical needs, including cancer, infectious diseases, diabetes, and cardiovascular conditions. Renowned for its high-quality products and patient-centric approach, Merck holds a significant position within the global healthcare ecosystem.

The company's product portfolio spans both human and animal health sectors. In the human health segment, Merck offers groundbreaking treatments such as Keytruda (cancer immunotherapy), Gardasil (HPV vaccine), Januvia/Janumet (diabetes treatment), and Bridion (reversal of neuromuscular blockade). Furthermore, in the veterinary field, Merck contributes to animal welfare by providing a range of pharmaceuticals, vaccines, and health management solutions under brands like Nuflor, Bovilis, Safe-Guard, and Bravecto. Technological innovation is at the heart of Merck's research and development (R&D) strategy. The company leverages advanced technologies, including artificial intelligence and machine learning, to accelerate drug discovery processes and develop more effective therapeutic interventions. Strategic collaborations with leading biotechnology and pharmaceutical firms, such as Daiichi Sankyo, AstraZeneca, Moderna, and Eisai, bolster the company's innovative pipeline.

Merck serves a vast global market, with operations extending from the United States to Asia, Europe, and Latin America, addressing the health needs of diverse patient and animal populations across different geographies. Its target demographics are broad, encompassing individuals with cancer, diabetes, children, the elderly, as well as farm animals and companion animals. Through robust distribution networks and close relationships with local healthcare systems, Merck has achieved significant success in delivering its products to those in need. Market leadership is particularly evident in the oncology and vaccine sectors. The company's global reach holds the potential to make a difference even in regions with limited access to healthcare.

Merck's future trajectory is shaped by its ongoing R&D investments, strategic partnerships, and focus on emerging therapeutic areas. The company is actively working on promising projects in fields such as Alzheimer's disease, rare diseases, and the prevention of infectious diseases. Advancements in digital health solutions and personalized medicine are also guiding the company's strategic direction. Committed to sustainability and corporate social responsibility, Merck continues to operate with a vision of solving global health challenges and building a healthier future. By integrating scientific excellence with patient-centricity, the company aims to maintain its pioneering role in the healthcare sector in the years to come.

Economic Moat Merck's sustainable competitive advantage stems from its extensive and innovative drug portfolio, particularly its strong patent-protected and clinically validated products in cancer immunotherapy (e.g., Keytruda). This is further supported by its robust global distribution network, established brand recognition, and strategic collaborations with leading research institutions, all of which solidify its market leadership.
CEO Mr. Robert M. Davis J.D.
Employees 73,000
Headquarters United States
Market Competitors
Smart Tags
#Healthcare #Pharmaceuticals #Biotechnology #NASDAQ #Oncology #Vaccines #GlobalHealth